Vitreomacular Adhesion vs. Vitreomacular Traction: What Is the Difference?
Understanding the Vitreoretinal Interface
The space inside the eye is filled with a clear, gel-like substance called the vitreous. It connects to the surface of the retina, including the macula, which is the central part of the retina responsible for sharp, detailed vision. Problems can arise when this connection does not separate as it should during the natural aging process.
As part of normal aging, the vitreous gradually liquefies and begins to pull away from the retinal surface. This process is called posterior vitreous detachment. For most people, this happens without causing any harm, and the vitreous separates cleanly from the retina.
Vitreomacular adhesion, or VMA, occurs when the vitreous separates from most of the retina but remains attached to the macula in a small, focused area. On imaging, the retinal layers beneath the attachment appear completely normal. There is no pulling or distortion of the tissue. VMA is defined as an attachment within about 3 millimeters of the fovea, which is the very center of the macula, with no change to the retinal structure. Many people with VMA have no symptoms, and the attachment may release on its own over time.
Vitreomacular traction, or VMT, develops when that same focal attachment begins to exert a pulling force on the macular tissue. This mechanical traction distorts the retinal architecture in ways that are clearly visible on imaging. Changes may include thickening of the central macula, separation of retinal layers forming small cysts, lifting of the foveal surface, or accumulation of fluid beneath the retina. VMT can cause noticeable symptoms including blurred or distorted central vision.
In some cases, the tractional forces of VMT become strong enough to create a defect in the foveal tissue itself, resulting in a full-thickness macular hole. A macular hole causes more significant central vision loss and typically requires surgical repair. The possibility of macular hole formation is one of the key reasons VMT is monitored closely and treated when appropriate.
How These Conditions Are Diagnosed
Accurate diagnosis of VMA and VMT relies on detailed imaging of the macula and a thorough clinical evaluation. The distinction between these two conditions depends on precisely what the imaging shows at the vitreoretinal interface, the point where the vitreous meets the retinal surface.
Optical coherence tomography, commonly called OCT, is the primary tool for evaluating VMA and VMT. This non-invasive imaging technology produces high-resolution cross-sectional images of the macula that clearly show the vitreous attachment and any resulting changes to the retinal layers. Serial OCT scans taken at regular intervals allow your retina specialist to track whether the condition is stable, resolving, or progressing over time.
An internationally recognized classification system based on OCT findings divides both conditions into focal and broad categories depending on the size of the vitreous attachment. VMT is further described as isolated or concurrent with other findings such as an epiretinal membrane, which is a thin layer of scar tissue growing over the retinal surface, or a macular hole. This classification guides treatment decisions and helps predict how a condition is likely to behave.
Visual acuity testing measures the functional impact of the condition on your eyesight. An Amsler grid test helps detect and track metamorphopsia, which is the perception that straight lines appear wavy or distorted. A dilated fundus examination allows your provider to directly view the macular surface and identify any concurrent conditions. In selected cases, OCT angiography may be used to evaluate the blood vessels beneath the area of traction.
Who Is at Risk?
VMA and VMT are related to the natural aging process of the vitreous, which means certain groups are more likely to develop them. Understanding risk factors helps explain why these conditions are monitored in some patients and not others.
VMA and VMT are most common in older adults, as the vitreous changes associated with aging are the underlying cause. Women are affected more frequently than men. The conditions tend to occur in people who have not undergone cataract surgery, since surgery involving the lens can accelerate vitreous separation. VMA in particular is relatively common and is often discovered incidentally during OCT imaging performed for other reasons.
Smaller, more focused adhesions may produce more concentrated traction compared to broader attachments, which tend to distribute the pulling force more evenly. The presence of a concurrent epiretinal membrane appears to reduce the likelihood that enzymatic treatment will be effective. The natural course of VMT varies widely, with some cases resolving on their own and others progressing toward a macular hole. Your retina specialist takes all of these factors into account when recommending a management plan.
Signs and Symptoms
The symptoms associated with VMA and VMT differ considerably because of the difference in what is happening to the retinal tissue. Knowing what to watch for can help you seek care at the right time.
Most people with vitreomacular adhesion experience no symptoms at all. Because the retinal architecture is not being disturbed, central visual acuity is typically preserved. Some patients notice mild floaters related to the ongoing vitreous separation process, but these are not caused by the adhesion itself. VMA is frequently found by chance during an eye exam or OCT performed for an unrelated reason.
Patients with vitreomacular traction may notice blurred central vision, wavy or distorted appearance of straight lines, and difficulty with tasks like reading or recognizing faces. The degree of visual disturbance generally reflects the severity of the macular distortion seen on OCT, though some patients have moderate imaging findings with relatively mild symptoms. If a macular hole forms, patients typically notice a more pronounced blur or a dark spot in the center of their vision. Any new central visual disturbance should be evaluated promptly.
Treatment Options
The right treatment for VMA or VMT depends on the severity of the condition, the degree of visual impact, and how the condition is changing over time. Options range from careful observation to office-based injection to surgery.
For asymptomatic VMA and for VMT that is stable with minimal symptoms, observation with regular OCT monitoring is often the most appropriate approach. Because a meaningful number of VMT cases resolve spontaneously as the vitreous continues to separate, a period of watchful waiting is reasonable in many situations. Your retina specialist monitors for signs of progression, including increasing macular distortion, declining visual acuity, or the development of a macular hole. If the condition remains stable, ongoing observation avoids the risks associated with intervention.
Monitoring at home with an Amsler grid, a simple printed chart of straight lines, can help detect any changes in vision between clinic visits. Report new or worsening distortion to your specialist right away.
Ocriplasmin, sold under the brand name Jetrea, is an enzyme administered as a single injection into the vitreous cavity in an office setting. It works by dissolving the protein bonds that hold the vitreous to the retinal surface, potentially releasing the traction without surgery. The strongest candidates for ocriplasmin are patients with focal VMT, a small adhesion diameter, no concurrent epiretinal membrane, and a natural lens still in place. Your retina specialist determines whether this treatment is appropriate for your specific situation.
Pars plana vitrectomy is a surgical procedure in which the vitreous gel is removed from the eye, directly releasing the traction on the macula. It is the definitive treatment for progressive VMT, VMT accompanied by a macular hole, and cases that do not respond to observation or enzymatic treatment. The procedure is performed under local anesthesia and often includes peeling of the internal limiting membrane, a thin layer on the retinal surface, to reduce the chance of recurrence. Vitrectomy can be combined with macular hole repair when needed and achieves resolution of traction in the vast majority of treated eyes.
What to Expect After Treatment
Recovery and follow-up vary depending on which treatment path is chosen. Your retina specialist provides specific guidance based on your individual case and monitors your healing through regular visits and imaging.
If your condition is being monitored, your specialist schedules follow-up visits at regular intervals with OCT imaging to check for any changes. If the vitreous releases on its own, the macular structure typically normalizes and any visual symptoms tend to improve. If the condition advances, your specialist discusses the right time to consider treatment and which option is most appropriate.
Following an ocriplasmin injection, you may experience temporary floaters, blurred vision, and light sensitivity as the vitreous reorganizes. These effects generally resolve over days to weeks. Follow-up OCT imaging confirms whether the vitreous has successfully released from the macula. If the adhesion has not resolved, vitrectomy may be considered as the next step.
Recovery after vitrectomy involves a period of limited activity, particularly if a gas bubble is placed in the eye during surgery to support healing. Visual improvement is gradual and may continue for weeks to months as the macula recovers. If a macular hole was repaired at the same time, face-down positioning may be required for a period after surgery to help the tissue close properly. Your retina specialist provides detailed recovery instructions and tracks your progress through follow-up visits and OCT imaging.
Frequently Asked Questions
The following questions address common points of uncertainty about VMA and VMT that patients often raise when deciding how to manage these conditions.
VMA on its own does not distort the retinal tissue, so it does not typically pose an immediate danger to your vision. The main concern is that it may develop into VMT over time, which is why periodic monitoring is important. Your retina specialist can tell you how often you should be seen based on the characteristics of your specific adhesion. If symptoms change between visits, an earlier appointment is warranted.
The decision to treat versus observe depends on several factors, including whether your symptoms are affecting daily activities, whether the OCT shows the traction is increasing, and whether there are signs that a macular hole may be forming. Mild, stable VMT with minimal visual impact is often appropriate to observe. Progressive VMT with worsening distortion or declining acuity is more likely to benefit from intervention. Your retina specialist weighs these factors together rather than relying on any single finding.
Yes, spontaneous release of VMT does occur in a portion of patients as the vitreous continues to separate naturally. This is one reason observation is a reasonable first approach for many cases. When the vitreous releases on its own, macular structure often improves and symptoms typically diminish. However, not all cases resolve spontaneously, and some progress to a macular hole, which is why ongoing monitoring remains essential even during a watchful waiting period.
If ocriplasmin does not achieve release of the vitreous attachment, vitrectomy is the established next step. This transition is not uncommon, and the fact that ocriplasmin was tried first does not make subsequent surgery more complicated. Your retina specialist monitors the response to the injection through follow-up OCT and discusses the timeline for surgical options if the injection does not produce the desired result.
Visual recovery depends on how much structural damage the traction caused before treatment and how well the macula heals afterward. When VMT is treated before significant damage occurs, outcomes tend to be more favorable. If a macular hole was present and repaired, recovery is generally more gradual and the degree of improvement varies by individual. Your retina specialist can give you a realistic picture of expected recovery based on your OCT findings and the duration of the condition.
You should seek prompt evaluation if you notice a sudden new dark spot in your central vision, a significant increase in line distortion, or a rapid decline in central visual acuity. These changes can indicate that VMT has progressed to a macular hole or that another condition has developed. Do not wait for a scheduled appointment if your symptoms change noticeably. Earlier evaluation almost always leads to better options for treatment.
Expert Retina Care at Rhode Island Eye Institute
Our retina specialists at Rhode Island Eye Institute, including Gaurav Gupta, M.D. and Pranjal Thakuria, M.D., are fellowship-trained and experienced in diagnosing and managing the full range of vitreomacular conditions, from incidental VMA to complex VMT requiring surgical repair. We use advanced OCT technology to guide every decision and work closely with each patient to develop a monitoring or treatment plan that fits their individual needs and goals. If you have been diagnosed with VMA or VMT, or if you are experiencing central vision changes that concern you, we welcome you to schedule a consultation with our team.